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Abstract: Methods that provide rapid access to radiolabeled antibodies are vital in the development of
diagnostic and radiotherapeutic agents for positron emission tomography (PET) or radioimmunother-
apy. The human hepatocyte growth factor receptor (c-MET) signaling pathway is dysregulated in
a number of malignancies including gastric cancer, and is an important biomarker in drug discovery.
Here, we used a photoradiochemical approach to produce 89Zr-radiolabeled onartuzumab (a monovalent,
anti-human c-MET antibody), starting directly from the fully formulated drug (MetMAb). Methods:
Simultaneous 89Zr-radiolabeling and protein conjugation was performed in one-pot reactions contain-
ing 89Zr-oxalate, the photoactive chelate DFO-aryl azide (DFO-ArN3) and MetMAb to give 89ZrDFO-
azepin-onartuzumab. As a control, 89ZrDFO-Bn-NCS-onartuzumab was prepared via a conventional
two-step process using pre-purified onartuzumab and DFO-Bn-NCS. Radiotracers were purified by using
size-exclusion methods and evaluated by radiochromatography. Radiochemical stability was studied in
human serum and immunoreactivity was determined by cellular binding assays using MKN-45 gastric car-
cinoma cells. PET imaging at multiple time points (0–72 h) was performed in female athymic nude mice
bearing subcutaneous MKN-45 xenografts. Biodistribution experiments were performed after the final
image. Tumor specificity of 89ZrDFO-azepin-onartuzumab was assessed by competitive inhibition (block-
ing) studies. Results: Initial photoradiosynthesis experiments produced 89ZrDFO-azepin-onartuzumab
in <15 min. with an isolated decay-corrected radiochemical yield (RCY) of 24.8%, a radiochemical pu-
rity (RCP) 90% and a molar activity (Am) of 1.5 MBq nmol-1. Reaction optimization improved the
radiochemical conversion (RCC) of 89ZrDFO-azepin-onartuzumab to 56.9±4.1% (n = 3), with isolated
RCYs of 41.2±10.6% (n = 3), and RCPs >90%. Conventional methods produced 89ZrDFO-Bn-NCS-
onartuzumab with isolated RCY >97%, RCP >97% and Am 14.0 MBq nmol-1. Both radiotracers
were immunoreactive and stable in human serum. PET imaging and biodistribution studies showed
high tumor uptake for both radiotracers. By 72 h, tumor and liver uptake reached 15.37±5.21 %ID
g-1, 6.56±4.03 %ID g-1, respectively for 89ZrDFO-azepin-onartuzumab (n = 4), and 21.38±11.57 %ID
g-1 and 18.84±6.03 %ID g-1 for 89ZrDFO-Bn-NCS-onartuzumab (n = 4). Blocking experiments gave a
statistically significant reduction in tumor uptake (6.34±0.47 %ID g-1) of 89ZrDFO-azepin-onartuzumab
(n = 4). Conclusion: Experiments demonstrate that photoradiosynthesis is a viable alternative approach
for producing 89Zr-radiolabeled antibodies direct in protein formulation buffer which reduces protein
aggregation and liver uptake.
DOI: https://doi.org/10.2967/jnumed.119.237180





Klingler, Simon; Fay, Rachael; Holland, Jason P (2020). Light-induced radiosynthesis of 89ZrDFO-






University of Zurich, Department of Chemistry, Winterthurerstrasse 190, CH-8057, Zurich, 
Switzerland 
* Corresponding Author:
Prof. Dr Jason P. Holland 
Tel: +41.44.63.53.990 
E-mail: jason.holland@chem.uzh.ch
Website: www.hollandlab.org  
First author:  
Simon Klingler 
E-mail: simon.klingler@chem.uzh.ch
Running Title: Photoradiosynthesis of 89Zr-antibodies 
Words (Main text): 4997 
  
Light-induced radiosynthesis of 89ZrDFO-azepin-onartuzumab for imaging 
the hepatocyte growth factor receptor 
Simon Klingler, Rachael Fay and Jason P. Holland* 
Page 2 
ABSTRACT 
Methods that provide rapid access to radiolabeled antibodies are vital in the development of 
diagnostic and radiotherapeutic agents for positron emission tomography (PET) or 
radioimmunotherapy. The human hepatocyte growth factor receptor (c-MET) signaling pathway 
is dysregulated in a number of malignancies including gastric cancer, and is an important 
biomarker in drug discovery. Here, we used a photoradiochemical approach to produce 89Zr-
radiolabeled onartuzumab (a monovalent, anti-human c-MET antibody), starting directly from the 
fully formulated drug (MetMAb).  
Methods: Simultaneous 89Zr-radiolabeling and protein conjugation was performed in one-pot 
reactions containing 89Zr-oxalate, the photoactive chelate DFO-aryl azide (DFO-ArN3) and 
MetMAb to give 89ZrDFO-azepin-onartuzumab. As a control, 89ZrDFO-Bn-NCS-onartuzumab 
was prepared via a conventional two-step process using pre-purified onartuzumab and DFO-Bn-
NCS. Radiotracers were purified by using size-exclusion methods and evaluated by 
radiochromatography. Radiochemical stability was studied in human serum and immunoreactivity 
was determined by cellular binding assays using MKN-45 gastric carcinoma cells. PET imaging 
at multiple time points (0–72 h) was performed in female athymic nude mice bearing subcutaneous 
MKN-45 xenografts. Biodistribution experiments were performed after the final image. Tumor 
specificity of 89ZrDFO-azepin-onartuzumab was assessed by competitive inhibition (blocking) 
studies. 
Results: Initial photoradiosynthesis experiments produced 89ZrDFO-azepin-onartuzumab in <15 
min. with an isolated decay-corrected radiochemical yield (RCY) of 24.8%, a radiochemical purity 
(RCP) ~90% and a molar activity (Am) of ~1.5 MBq nmol-1. Reaction optimization improved the 
radiochemical conversion (RCC) of 89ZrDFO-azepin-onartuzumab to 56.9±4.1% (n = 3), with 
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isolated RCYs of 41.2±10.6% (n = 3), and RCPs >90%. Conventional methods produced 89ZrDFO-
Bn-NCS-onartuzumab with isolated RCY >97%, RCP >97% and Am ~14.0 MBq nmol-1. Both 
radiotracers were immunoreactive and stable in human serum. PET imaging and biodistribution 
studies showed high tumor uptake for both radiotracers. By 72 h, tumor and liver uptake reached 
15.37±5.21 %ID g-1, 6.56±4.03 %ID g-1, respectively for 89ZrDFO-azepin-onartuzumab (n=4), and 
21.38±11.57 %ID g-1 and 18.84±6.03 %ID g-1 for 89ZrDFO-Bn-NCS-onartuzumab (n=4). 
Blocking experiments gave a statistically significant reduction in tumor uptake (6.34±0.47 %ID g-
1) of 89ZrDFO-azepin-onartuzumab (n=4).
Conclusions: Experiments demonstrate that photoradiosynthesis is a viable alternative approach 
for producing 89Zr-radiolabeled antibodies direct in protein formulation buffer which reduces 
protein aggregation and liver uptake. 
Keywords: Photoradiosynthesis, immuno-PET, antibodies, hepatocyte growth factor receptor (c-
MET), zirconium-89, MetMAb, onartuzumab 
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INTRODUCTION 
Monoclonal antibodies (mAbs) radiolabeled with 89Zr are important tools for non-invasive 
immuno-positron emission tomography (immuno-PET) of biomarker fluctuations during cancer 
diagnosis, progression and treatment. Existing methods to produce clinical-grade 89Zr-radiolabeled 
mAbs rely on multiple step processes. First, the protein is purified to remove formulation 
components that can interfere with the subsequent chemistry. Second, the mAb is functionalized 
with the chelate desferrioxamine B (DFO) and then re-purified to remove unreacted coupling 
reagents. Functionalization typically occurs by reacting the -NH2 of lysine residues forming 
amide bond with the activated ester of DFO-succinate,(1,2) or thioureas with DFO-Bn-NCS.(3) 
Importantly, the functionalized mAb is then characterized and stored (typically in saline, PBS or 
HEPES buffer) prior to 89Zr-radiolabeling.  
Current 89Zr-radiochemistry processes are highly successful and many 89Zr-radiolabeled 
mAbs have been evaluated in the clinic.(4) However, the radiosynthesis and characterization of 
89Zr-radiolabeled mAbs remains non-trivial, and production is restricted to specialist facilities. 
Automated synthesis and purification methods are likely to improve access to 89Zr-radiolabel 
mAbs(5) but other physical and regulatory issues associated with the isolation, characterization 
and long-term storage of the functionalized intermediate mAb are more challenging to address 
with existing chemistry. Antibody functionalization may alter the biophysical properties of the 
protein, and storage leads to questions over the long-term stability and viability of the radiolabeling 
precursor. These issues mean than some regulatory authorities require absorption, distribution, 
metabolism, excretion and toxicological (ADME-tox) profiling of the functionalized intermediate. 
Providing ADME-tox data entails both technical and financial challenges – producing enough 
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functionalized protein is non-trivial and requires a considerable, and often prohibitive, capital 
investment. Methods that avoid isolation of an intermediate are potentially advantageous. 
Cellular signaling by the human hepatocyte growth factor receptor (c-MET) pathway is 
dysregulated in various human cancers including gastric, breast, lung, ovarian and pancreatic 
cancer.(6) Dysregulation can occur in the form of overexpression and amplification of the c-MET 
gene which induces signaling cascades that influence tumor proliferation via the P13K/AKT and 
Ras/MAPK pathways.(7) Several MET inhibitors and anti-MET antibodies are under evaluation 
and imaging of c-MET expression has the potential to support the clinical trials of MET-targeted 
therapies.(8–11) 
Onartuzumab, (MetMAb, Genentech Inc. [Roche Group], South San Francisco, CA) is a 
humanized, one-armed monovalent anti-human c-MET antibody designed to bind the extracellular 
domain of c-MET and block activation by the hepatocyte growth factor (HGF; also known as 
scatter factor).(12) The monovalent design of onartuzumab was employed to avoid dimerization 
and activation of the c-MET receptor which leads to pro-angiogenic signal transduction.(13) 
MetMAb has been investigated in phase III trials(14) as a treatment for non-small-cell lung cancer 
(NSCLC) and onartuzumab has been used for immuno-PET with 89Zr or 76Br radionuclides, and 
for radioimmunotherapy with 177Lu.(8–11) 
Our group has recently developed a one-pot photoradiosynthesis approach for the 
simultaneous conjugation and 89Zr-radiolabeling of mAbs.(15–19) Here, we evaluated the 
photoradiosynthesis of 89Zr-radiolabeled onartuzumab starting from fully formulated MetMAb 
without pre-purification of the protein or isolation of an intermediate (Figure 1). 
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MATERIALS AND METHODS 
Full details are presented in the supporting information. 
Antibody Samples 
Onartuzumab (MW=99.16 kDa; 66 Lys; molar absorption coefficient, ε280=161,465 M-1 
cm-1) was supplied by Genentech as the formulated drug (MetMAb). Stock solutions of MetMAb
contained a protein concentration of 60 mg mL-1 formulated in 10 mmol L-1 histidine succinate, 
106 mmol L-1 trehalose dihydrate, and 0.02% polysorbate 20 at pH5.7. Protein samples were 
aliquoted and stored at -70oC.(20) 
Synthesis, Photochemistry and Radiochemistry 
[89Zr][Zr(C2O4)4]4-(aq.) was obtained as a solution in ~1.0 M oxalic acid from PerkinElmer 
(Boston, MA, manufactured in The Netherlands) and was used without further purification. 
Conjugation and radiolabeling of DFO-Bn-NCS-onartuzumab was performed in accordance with 
previously reported methods.(3) The photoactive chelate DFO-ArN3 was synthesised and 
characterized previously and photoradiochemical conjugation reactions were performed in 
accordance with methods reported by Patra et al.(17) Note the compound undergoes slow 
degradation over ~4 months at -20oC. Fresh samples should be isolated prior to use. 
Stability Studies 
The stability of 89Zr-DFO-azepin-onartuzumab and 89Zr-DFO-Bn-NCS-onartuzumab with 
respect to change in radiochemical purity, loss of radioactivity from the mAb and/or change in 
immunoreactivity was investigated in vitro by incubation in solutions of human serum for 48h at 
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37ºC. The radiochemical purity was determined by radiochromatography using a size-exclusion 
column coupled to a high-performance liquid chromatography system (HPLC).  
Cell Binding Assays 
For cell binding assays, the human gastric cancer cell line MKN-45 (c-MET 
overexpressing, Leibniz Institute DSMZ-German collection of Microorganisms and Cell cultures 
[ACC-409]) was used. Immunoreactivity was determined using a procedure adapted from Lindmo 
et al.(21) 
Animals and Xenograft Models 
Animal experiments were conducted in accordance with an experimentation licence 
approved by the Zurich Canton Veterinary Office, Switzerland. Female athymic nude mice 
(Crl:NU(NCr)-Foxn1nu, 20–25 g, 4–8 weeks old) were obtained from Charles River Laboratories 
Inc. (Freiburg im Breisgau, Germany). Tumours were induced on the right shoulder or flank by 
sub-cutaneous (s.c.) injection of approx. 2.5×106 cells suspended in 200 μL of a 1:1 v/v mixture 
of PBS and reconstituted basement membrane (Corning® Matrigel® Basement Membrane Matrix, 
obtained from VWR International).(22) 
Small-Animal PET Imaging 
PET imaging experiments were conducted on a Genesis G4 PET/X-ray scanner (Sofie 
Biosciences, Culver City, CA). Radiotracers were administered 200 µL sterile PBS by intravenous 
(i.v.) tail-vein injection (t=0 h). Approximately 5 minutes prior to recording PET images, mice 
were anesthetized by inhalation of 2-3% isoflurane (Baxter Healthcare, Deerfield, IL)/oxygen gas 
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mixture (~5 L/min) and placed on the scanner bed. PET images were recorded at various time-
points between 0–72 h post-injection (see supporting information for full details). 
Biodistribution Studies 
Tumor-bearing mice were randomized before the study. Animals (n=4, per group) were 
euthanized by exsanguination under anaesthesia. Tissue samples were removed, rinsed in water, 
dried in air for ~2 min., weighed and counted on a gamma-counter for accumulation of 89Zr-
radioactivity. Full details are presented in the supporting information.  
Statistical Analysis 
Data were analyzed by using the unpaired, two-tailed Student’s t-test. Differences at the 
95% confidence level (P<0.05) were considered to be statistically significant. 
RESULTS 
Radiochemistry 
The synthesis, characterization, and reactivity of the photoactive chelate DFO-ArN3 (1) 
was reported elsewhere.(17) Briefly, a neutralized stock solution of [89Zr(C2O4)4]4– (89Zr-oxalate) 
was added to an open glass vial containing a mixture of compound 1 and formulated onartuzumab 
with an initial chelate-to-mAb ratio of 6.15-to-1, and a final pH ~8–9. The reaction was stirred 
gently at room temperature and irradiated directly for 10 min. by using a light emitting diode 
source (LED, max=364.5 nm, FWHM=9.1 nm, power=263 mW, Supplemental Figure 1). Prior 
tests determined that this experimental geometry was sufficient to affect complete photochemical 
reaction of DFO-ArN3.(17) After quenching the reaction with excess DTPA to ensure that any free 
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89Zr4+ ions that may non-specifically bind to proteins were solubilized, crude aliquots were 
analyzed by radioactive instant thin-layer chromatography (radio-iTLC; Supplemental Figure 2), 
manual size-exclusion chromatography (SEC) using PD-10 gel filtration columns (Figure 2A), and 
high-performance liquid chromatography coupled to a size exclusion gel column (SEC-HPLC; 
Figure 2B). Chromatographic methods on the crude reaction samples confirmed that 89Zr-activity 
was bound to the protein as evidenced by a peak in the PD-10 chromatograms in the 0.0–1.6 mL 
fraction (radiochemical conversion, RCC ~25.0%, Figure 2A red trace) and by a radioactive peak 
in the SEC-HPLC that coincided with the retention time of onartuzumab at ~14.1 min. (RCC 
~35.0%, Figure 2B red trace). A fraction of the reaction mixture was purified manually by using 
preparative PD-10 SEC and aliquots of the purified sample were reanalyzed using the same 
chromatographic methods (Figure 2, and Supplemental Figure 2, green traces). After purification, 
the photoradiochemically synthesized product, 89ZrDFO-azepin-onartuzumab was isolated with a 
decay-corrected radiochemical yield (RCY) of 24.8%, and a radiochemical purity of ~90% as 
measured by both analytical PD-10 SEC, and by SEC-HPLC. The final molar activity was 
~1.5MBq nmol-1 of protein at an activity concentration of 3.87MBq mL-1. 
As a control for use in the biological assays that followed, we also prepared 89ZrDFO-Bn-
NCS-onartuzumab via a traditional multiple step procedure that involved pre-purification of 
onartuzumab from the formulation buffer, functionalization with the commercially available DFO-
Bn-NCS reagent, and subsequent 89Zr-radiolabeling of the purified intermediate using established 
methods.(1,2) For comparison, crude and purified aliquots of 89ZrDFO-Bn-NCS-onartuzumab 
were tested using the same chromatographic methods as described above (Figure 2 and 
Supplemental Figure 2, crude samples = black traces, purified samples = blue traces). 89ZrDFO-
Bn-NCS-onartuzumab was obtained with an isolated decay-corrected RCY of >97%, a RCP >97% 
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(measured by both analytical PD-10 SEC and by SEC-HPLC), a molar activity of ~14.0MBq nmol-
1 of protein, and an activity concentration of ~19.0MBq mL-1. The radiochemical purity of 
89ZrDFO-Bn-NCS-onartuzumab was higher than that of 89ZrDFO-azepin-onartuzumab produced 
by photoradiosynthesis primarily because the efficiency of the PD-10 columns decreased when 
separating a larger fraction of radioactive ‘small-molecules’ from the labeled protein, and also 
because the pore size and loading capacity of standard 2.5 mL PD-10 columns provides insufficient 
resolution. This issue can be readily resolved by using larger gel filtration columns, alternative 
gels with finer particle sizes, or by switching to spin-column SEC methods. 
Purified samples of 89ZrDFO-Bn-NCS-onartuzumab produced via the conventional 
multiple step route contained ~24% of aggregated protein which increased from ~15% in the crude 
mixtures (Figure 2B, asterisk). In contrast, photoradiosynthesis of 89ZrDFO-azepin-onartuzumab 
using formulated MetMAb gave an aggregated protein fraction of <4% in the final product. 
Stability Studies 
Isolated samples of 89ZrDFO-azepin-onartuzumab and 89ZrDFO-Bn-NCS-onartuzumab 
were incubated in human serum at 37oC for up to 48h. Radiochemical chemical stability with 
respect to loss of 89Zr activity from the protein fraction was analyzed by SEC-HPLC 
(Supplemental Figure 3). Both radiotracers were found to be stable under these conditions with 
essentially no loss of 89Zr-activity from the mAb. 
Cellular Binding and Immunoreactivity  
The binding and specificity of 89ZrDFO-azepin-onartuzumab and 89ZrDFO-Bn-NCS-
onartuzumab to the target protein was evaluated in vitro by using cellular association assays with 
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c-MET positive and overexpressing MKN-45 gastric adenocarcinoma cells (Supplemental Figure
4). Blocking studies with excess MetMAb confirmed the binding specificity, and standard Lindmo 
transformations gave immunoreactive fractions of  38% for 89ZrDFO-azepin-onartuzumab and 
54% for 89ZrDFO-Bn-NCS-onartuzumab.(21) The relatively low immunoreactive fractions for 
both radiotracers was consistent with our previous characterization data using 68GaHBED-CC-
azepin-onartuzumab(18) and is likely due to the well-documented limitations of the Lindmo 
assay.(23–25) 
Radiochemical Optimization 
A series of photoradiolabeling experiments were performed to optimize the reaction 
parameters and obtain higher isolated RCYs of 89ZrDFO-azepin-onartuzumab. The effect of 
changing the initial chelate-to-mAb ratio and the initial protein concentration are shown in Figure 
3A and 3B, respectively (see also Supplemental Table 1). After optimization, the radiochemical 
conversion to give 89ZrDFO-azepin-onartuzumab was improved to an average of 58.1±3.4% 
(n=10; measured by SEC-HPLC), with an isolated decay-corrected RCY of 36.6±10.3% (n=9), 
and an average RCP of 91.2±1.1% (n=9; measured by SEC-HPLC). The effect of not stirring the 
reaction was also measured and a RCY of 56.5% was obtained indicating that stirring the solutions 
had no influence in our experimental geometry. Experiments showed that by using initial chelate-
to-mAb ratios ranging from 4.62 to 0.77 had no effect on the RCY. In contrast, the reaction was 
very sensitive to changes in protein concentration. When the initial protein concentrations were 
reduced to 12µM, the measured RCYs decreased dramatically to <30%, and for protein 
concentrations 1µM, RCYs ranged between 5.6% to 13.7% (n=4; Supplemental Table 1). 
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PET Imaging 
Temporal immuno-PET imaging of 89ZrDFO-Bn-NCS-onartuzumab and 
photoradiolabeled 89ZrDFO-azepin-onartuzumab was performed female athymic nude mice 
bearing subcutaneous MKN-45 xenografts on the right flank/shoulder (n=4 mice/group). A third 
group of animals (n=4 mice) received a low molar activity formulation of the same batch of 
photoradiolabeled 89ZrDFO-azepin-onartuzumab diluted with non-radioactive MetMAb as a 
blocking group control to measure the specificity of tumor uptake in vivo. PET images recorded at 
6h and 72h post-radiotracer administration are shown in Figure 4 and further tomographic and 
maximum intensity projection (MIP) images are shown Supplemental Figures 5 and 6, 
respectively. Image quantification based on volume-of-interest (VOI) analysis with data presented 
in units of percentage injected dose per cubic centimeter (%ID cm-3) are shown in Figure 5 and 
Supplemental Figure 7. PET imaging revealed that photoradiolabeled 89ZrDFO-azepin-
onartuzumab is a viable radiotracer for quantifying c-MET expression in vivo. 89ZrDFO-azepin-
onartuzumab displayed a prolonged circulation time and specific tumor uptake that increased from 
8.8±0.5%ID cm-3 after 6 h to 13.7±2.9%ID cm-3 at 72 h post-administration. Tumor uptake of 
89ZrDFO-azepin-onartuzumab in the blocking group showed a statistically significant difference 
with only 4.3±2.2%ID cm-3 after 6 h (Student’s t-test P-value=0.023) and peak at only 6.6±2.4%ID 
cm-3 at 72h (P-value=0.001). In comparison, tumor-associated uptake of 89ZrDFO-Bn-NCS-
onartuzumab showed a higher overall uptake and increased from 14.3±1.7%ID cm-3 after 6h (P-
value versus the normal photoradiolabeled group = 0.005) to 19.7±4.8%ID cm-3 by 72h (P-
value=0.088). Notably, by 72h no statistically significant difference was observed between the 
tumor uptake of the two radiotracers. 
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Quantitative analysis of the PET images also revealed a statistically significant lower 
accumulation of 89Zr activity in the liver for 89ZrDFO-azepin-onartuzumab (7.5±2.8%ID cm-3) 
versus 89ZrDFO-Bn-NCS-onartuzumab at 72h (17.8±4.0%ID cm-3; P-value=0.007). For the 
89ZrDFO-azepin-onartuzumab blocking group, the additional administered mass of protein led to 
an increased accumulation and retention of 89Zr activity in the kidneys (18.9±7.5%ID cm-3 versus 
8.5±0.7%ID cm-3 for the normal group at 72h; P-value=0.05). A similar dose-dependent change 
in kidneys uptake was observed for 68GaHBED-CC-azepin-onartuzumab confirming that this 
phenomenon is unrelated to the radionuclide or chelate.(18) 
Effective Half-life Measurements 
Whole-body activity was measured in each mouse by using a dose calibrator to determine 
the effective (t1/2(eff)/h) and biological (t1/2(biol)/h) half-lives of the two radiotracers 
(Supplemental Figure 8). 89ZrDFO-azepin-onartuzumab had a t1/2(eff)=21.8±4.3h and a calculated 
t1/2(biol)=30.2±10.8h compared with t1/2(eff)=31.9±5.6h and t1/2(biol)=53.8±5.6h for 89ZrDFO-
Bn-NCS-onartuzumab. No difference was observed in the measured values of t1/2(eff) for the 
normal and blocking groups of 89ZrDFO-azepin-onartuzumab which confirmed that even though 
kidney uptake increased in animals that received a blocking dose of MetMAb, whole-body 
radiotracer excretion did not change. 
Biodistribution Studies 
After the final imaging time point at 72h, animals were euthanized by terminal exsanguination 
under anesthesia and 15 tissues, including the tumors, were collected for accurate quantification 
of the accumulated 89Zr activity (Figure 6, Supplemental Table 2 and Supplemental Figures 9 and 
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10). Biodistribution data are consistent with the distribution patterns observed from the 
quantitative PET. Measured accumulation of activity in the tumor and liver was 15.4±5.2%ID g-1 
and 6.6±4.0%ID g-1, for 89ZrDFO-azepin-onartuzumab respectively, whereas for 89ZrDFO-Bn-
NCS-onartuzumab uptake values were 21.4±11.6%ID g-1 and 18.8±6.0%ID g-1, respectively. With 
the exception of the activity accumulation in the liver and spleen (P-value=0.018 and 0.022), no 
statistically significant differences were observed between the 89ZrDFO-azepin-onartuzumab and 
89ZrDFO-Bn-NCS-onartuzumab groups. Comparison of the tumor-associated activity for the 
normal and blocking groups (6.3±1.0%ID g-1) that received 89ZrDFO-azepin-onartuzumab 
confirmed that tumor uptake for the photoradiolabeled product was specific (P-value=0.03). No 
statistically significant differences were observed in the measured tumor-to-tissue contrast ratios 
between the conventional and photoradiolabeled products (Supplemental Figure 10). Overall, the 
cellular assays, PET imaging, and biodistribution data confirm that both 89ZrDFO-azepin-
onartuzumab and 89ZrDFO-Bn-NCS-onartuzumab are viable radiotracers for measuring c-MET 
protein expression in gastric adenocarcinomas. 
DISCUSSION 
Extensive spectroscopic and computational studies have established the mechanism of 
photochemical activation of the ArN3 group and comprehensive details are given in our previous 
reports.(15–17,19) Briefly, light-induced activation of the [89ZrDFO-ArN3]+ produces the highly 
reactive open-shell singlet nitrene (life time,  ~1 ns). This nitrene species is too short-lived to 
undergo efficient bimolecular chemistry with the protein (or indeed the solvent). Instead, the 
singlet nitrene undergoes rapid intramolecular rearrangement to give first a bicyclic benzazirene 
which then ring-opens to give a 7-membered ketenimine heterocycle which acts as the key 
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electrophilic intermediate.(26–29) Remarkably, this ketenimine intermediate reacts preferentially 
with primary (and secondary) amines over oxygen-based nucleophiles with a low kinetic barrier 
(~50 kJ mol-1) that is thermally accessible under ambient conditions. This phenomenon favors 
bimolecular reactions with the comparatively low levels of protein over background quenching 
reactions.  
Advantages of using our photoradiosynthesis approach to produce 89Zr-radiolabeled mAbs 
include: i) Rapid reaction kinetics where both the radiolabeling and protein conjugation steps occur 
at the same time and are complete in <10 min.(30) ii) Chemoselective functionalization of lysine 
side-chains by nucleophilic attack on the electrophilic ketenimine intermediate.(26,28) iii) 
Tolerance of the photochemical process to water, oxygen, salts and clinical-grade mAb 
formulation buffers (including histidine) that are essential to maintain protein stability. Our 
experimental data recorded in vitro and in vivo support this statement where 89ZrDFO-azepin-
onartuzumab exhibits a lower degree of protein aggregation and decreased accumulation of 89Zr 
activity in the liver compared to 89ZrDFO-Bn-NCS-onartuzumab. iv) Photoactivation occurs at 
wavelengths where antibodies do not absorb. Hence, the photoreaction does not damage the 
structure and function of the biological vector.(18) v) Unlike conventional methods, 
photoradiosynthesis is amenable to full automation which may streamline the efforts required to 
produce 89Zr-mAbs. Finally, vi) the one-pot photoradiosynthesis procedure produces formulated 
89Zr-mAbs without the need to isolate, characterize and store the functionalized intermediates. This 
novel concept has the potential to change the way in which 89Zr-mAbs are produced in the clinic 
because it eliminates issues over the long-term stability of the functionalized intermediates and 
circumvents the technical and financial issues of performing ADME-tox studies on the 
intermediate. 
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In spite of the many attractive features, photoradiosynthesis of 89Zr-mAbs has several 
limitations that require further research. Prior experiments using different photoactive chelates, 
radionuclides and proteins have revealed strong variations in the radiochemical conversions and 
isolated RCYs. Photoradiosynthesis using [89ZrDFO-ArN3]+ has (so far) afforded the highest 
RCCs with values in this study peaking at 58.1±3.4% and in previous work 89ZrDFO-azepin-
trastuzumab was obtained in RCCs of 67% to 88%.(17) Studies using 68Ga3+ and 111In3+ 
radionuclides combined with either aza-macrocyclic or acyclic chelates afforded lower photo-
induced RCCs in the range 4% to ~25%.(15,16,18,19) The light-induced chemistry is highly 
dependent on the experimental geometry. Although kinetic studies have shown that the photo-
initiation step is highly efficient, and linearly dependent on photon flux,(15,17) the photon beam 
shape, focal point, reaction volume, and potential scattering or absorption of the incident light by 
the reaction vessel or chemical components in the mixture can have a dramatic impact on the 
observed RCCs. Experimental RCCs also show a steep dependency on the initial protein 
concentration. 
Another issue is the poor solubility of DFO-ArN3 in aqueous conditions – it dissolves at 
high pH>10 but precipitates readily on adjusting the pH to the optimum window of between 7.5–
9.0 required for the photochemical reaction.(17) Higher pH values cannot be used because many 
antibodies do not tolerate highly basic conditions, and our experiments have found that at pH~9.0, 
the measured RCCs decrease due to hydrolysis of the ketenimine intermediate by hydroxide 
anions. The solubility issues associated with DFO-ArN3 can potentially be addressed by using the 
strategy of Codd and co-workers(31) who incorporated ether groups in the chelate backbone, or 
by the addition of polyethylene glycol (PEG) chains between the chelate and the photoactive ArN3 
group.(15,16) At present, variations in the RCCs are also the main reason why it is more difficult 
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to purify the 89Zr-mAb from the photochemical reaction mixture than from conventional syntheses 
that often show quantitative radiolabeling. These purification issues are primarily technical in 
nature and can be solved by using alternative purification methods such as spin column 
centrifugation. Nevertheless, improving the reaction efficiency remains our primary goal. Much 
work remains before photoradiosynthetic methods can be standardized. However, the results 
presented here demonstrate that photoradiosynthesis – starting from formulated antibody stock 
solutions – yields viable radiotracers which sets an important and encouraging precedent for future 
use of this technology in Nuclear Medicine. 
CONCLUSION 
89Zr-radiolabeled onartuzumab was produced via two separate synthesis routes involving 
traditional thermally-mediated conjugation using isothiocyanate (NCS) chemistry and an 
alternative light-induced photochemical conjugation process using aryl azide (ArN3) chemistry. 
These approaches yielded 89ZrDFO-Bn-NCS-onartuzumab and 89ZrDFO-azepin-onartuzumab 
which were both shown to be viable radiotracers targeting the c-MET receptor in gastric 
adenocarcinoma. Switching the synthesis to a simultaneous, one-pot photochemical conjugation 
and 89Zr-radiolabeling route has the advantage that the photochemistry is compatible with standard 
components of antibody formulation buffers. The photoradiosynthesis was also completed in <15 
min. and gave a final product that displayed a decreased tendency toward protein aggregation, and 
consequently lower uptake in the liver and spleen. Radiochemical conversions were systematically 
improved by investigating different reaction parameters including the initial chelate-to-antibody 
ratio and the protein concentration. Further studies are required to improve the isolated 
radiochemical yield, radiochemical purity, and molar activity of the final products but these data 
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encourage the development of photoradiosynthesis as an alternative labeling strategy for the 
production of clinical-grade 89Zr-radiolabeled proteins. 
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Key points 
Question: Can photochemical methods be used to produce viable radiopharmaceuticals for 
immuno-PET? 
Pertinent findings: Experiments demonstrate that a one-pot, simultaneous light-induced chemical 
conjugation and radiolabeling process can produce 89ZrDFO-azepin-onartuzumab for imaging c-
MET receptors, starting directly from a fully formulated solution of MetMAb. 
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Implications for patient care: New methods to access radiolabeled antibodies has the potential to 
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Figure 1. Multiple component photoradiosynthesis of monovalent (one-armed) 89ZrDFO-azepin-
onartuzumab starting from fully formulated MetMAb, the photoactive chelate DFO-ArN3, and 
[89Zr(C2O4)4]4– (89Zr-oxalate). 
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Figure 2. Chromatographic data on the radiosynthesis of 89ZrDFO-azepin-onartuzumab and 
89ZrDFO-Bn-NCS-onartuzumab showing (A) elution profiles from analytical PD-10 size-
exclusion columns, and (B) SEC-HPLC radiochromatograms, for the crude and purified samples 
of each radiotracer. ‘’ indicates the retention time of small molecule impurities, ‘*’ indicates the 
elution of high molecular weight protein aggregates. See Supplemental Figure 2 for radio-iTLC 
data. 
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Figure 3. Radiochemical conversions (%) measured by SEC-HPLC methods for the optimization 
of the photoradiosynthesis of 89ZrDFO-azepin-onartuzumab with, (A) varying initial chelate-to-
mAb ratios (with a fixed protein concentration of 37.8 µM), and with (B) varying protein 
concentrations. See also Supplemental Table 1. 
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Figure 4. Temporal PET images recorded in athymic nude mice bearing MKN-45 tumors on the 
right flank for (left) 89ZrDFO-Bn-NCS-onartuzumab, (middle) 89ZrDFO-azepin-onartuzumab 
(normal group), and (right) 89ZrDFO-azepin-onartuzumab (blocking group). T=tumor, H=heart, 
L=liver, Sp=spleen. Planar images are shown through the tumor center. See also Supplemental 
Figures 5 and 6. 
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Figure 5. Time-activity bar chart showing the mean activity (%ID cm-3) associated with different 
tissues versus time. 89ZrDFO-Bn-NCS-onartuzumab (blue bars; n=4), 89ZrDFO-azepin-
onartuzumab (normal group; red-to-yellow bars; n=4), and 89ZrDFO-azepin-onartuzumab 
(blocking group; grey-to-white bars; n=4). See also Supplemental Figure 7. 
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Figure 6. Bar chart showing ex vivo biodistribution data (%ID g-1) for the uptake of 89ZrDFO-Bn-
NCS-onartuzumab (blue bars), 89ZrDFO-azepin-onartuzumab (normal group, white bars), and 
89ZrDFO-azepin-onartuzumab (blocking group, red bars) in mice bearing MKN-45 tumors at 72h 
post-injection. Student’s t-test: (ns) not significant, (*) P-value<0.05, (**) P-value<0.01, (***) P-
value<0.001. See also Supplemental Figures 9 and 10.  
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General details 
The synthesis and characterisation of DFO-ArN3 was reported elsewhere.(1) Unless otherwise 
stated, all chemicals were of reagent grade and purchased from SigmaAldrich (St. Louis, MO), 
Merck (Darmstadt, Germany), Tokyo Chemical Industry (Eschborn, Germany), abcr (Karlsruhe, 
Germany) or CheMatech (Dijon, France). Water (>18.2 MΩ·cm at 25 oC, Puranity TU 3 UV/UF, 
VWR International, Leuven, Belgium) was further purified by using Chelex resin to remove 
contaminant metal ions. Solvents for reactions were of reagent grade, and where necessary, were 
dried over molecular sieves. Evaporation of the solvents was performed under reduced pressure 
by using a rotary evaporator (Rotavapor R-300, Büchi Labortechnik AG, Flawil, Switzerland) at 
the specified temperature and pressure. Electronic absorption spectra were recorded using a 
NanodropTM OneC Microvolume UV-Vis Spectrophotometer (ThermoFisher Scientific, supplied 
by Witec AG, Sursee, Switzerland). Protein concentration was determined in accordance with 
the manufacturers protocol. 
Photochemistry 
Photochemical conjugation experiments were performed in transparent glass vials at the 
specified concentrations. Unless otherwise stated, photochemical reactions were typically stirred 
gently by adding a small magnetic stir bar to the reaction vial and employing a slow stirring rate 
(< 1000 rpm) to avoid potential damage to the protein. Detail procedures and reaction times are 
indicated in the experimental section. Ultra-violet irradiations were performed by using a 
portable light-emitting diode (LED 365 nm). The LED intensity was adjusted using a digital UV-
LED controller (Opsytec Dr. Gröbel GmbH, Ettlingen, Germany), where 100% corresponded to 
a power of approximately 263 mW at 365 nm. LED intensity was measured by using a S470C 
Thermal Power Sensor Head Volume Absorber, 0.25 – 10.6 µm, 0.1 mW – 5W, Ø15 mm. The 
temperature of all photochemical conjugation reactions was typically 23 ± 2 oC (ambient 
conditions). An experimentally measured emission spectrum of the LED light source and a plot 
of the power versus digitally controlled LED intensity (as a percentage of maximum current) are 
shown in Supplemental Figures 1A and 1B, respectively. The LED source (365 nm) had a linear 
response with changing LED intensity with a peak emission at 364.5 nm and a FWHM of 9.1 
nm. 
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Supplemental Figure 1. (A) Emission spectrum of the LED (365 nm), and (B) the measured 
power output (mW) versus the digitally controlled LED intensity (%). 
Radioactivity and radioactive measurements 
All instruments for measuring radioactivity were calibrated and maintained in accordance with 
previously reported routine quality control procedures.(2) [89Zr][Zr(C2O4)4]4-(aq.) was obtained 
as a solution in ~1.0 M oxalic acid from PerkinElmer (Boston, MA, manufactured by the BV 
Cyclotron VU, Amsterdam, The Netherlands) and was used without further purification. 
Radioactive reactions were monitored by using instant thin-layer chromatography (radio-iTLC). 
Glass-fibre iTLC plates impregnated with silica-gel (iTLC-SG, Agilent Technologies) were 
developed in using aqueous mobile phases containing DTPA (50 mM, pH7.1) and were analysed 
on a radio-TLC detector (SCAN-RAM, LabLogic Systems Ltd, Sheffield, United Kingdom). 
Radiochemical conversion (RCC) was determined by integrating the data obtained by the radio-
TLC plate reader and determining both the percentage of radiolabelled product (Rf = 0.0) and 
‘free’ 89Zr (Rf = 1.0; present in the analyses as [89Zr][Zr(DTPA)]–). Integration and data analysis 
were performed by using the software Laura version 5.0.4.29 (LabLogic). Appropriate 
background and decay corrections were applied as necessary. Radiochemical purities (RCPs) of 
labelled protein samples were determined by size-exclusion chromatography (SEC) using two 
different columns and techniques. The first technique used an automated size-exclusion column 
(Bio-Rad Laboratories, ENrich SEC 70, 10 ± 2 µm, 10 mm ID x 300 mm) connected to a Rigol 
HPLC system (Contrec AG, Dietikon, Switzerland) equipped with a UV/visible detector 
(absorption measured at 220, 254 and 280 nm) as well as a radioactivity detector (FlowStar2 LB 
514, Berthold Technologies, Zug, Switzerland). Isocratic elution with phosphate buffered saline 
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(PBS, pH7.4) was used. The second method used a manual procedure involving size-exclusion 
column chromatography and a PD-10 desalting column (Sephadex G-25 resin, 85-260 µm, 14.5 
mm ID x 50 mm, >30 kDa, GE Healthcare). For analytical procedures, PD-10 columns were 
eluted with PBS. A total of 40 x 200 µL fractions were collected up to a final elution volume of 8 
mL. Note that the loading/dead-volume of the PD-10 columns is precisely 2.50 mL which was 
discarded prior to aliquot collection. For quantification of radioactivity, each fraction was 
measured on a gamma counter (HIDEX Automatic Gamma Counter, Hidex AMG, Turku, 
Finland) using an energy window between 480 – 558 keV for 89Zr (511 keV emission) and a 
counting time of 30 s. Appropriate background and decay corrections were applied throughout. 
PD-10 SEC columns were also used for preparative purification and reformulation of 
radiolabelled products (in sterile PBS; pH7.4) by collecting a fraction of the eluate corresponding 
to the high molecular weight protein (>30 kDa fraction eluted in the range 0.0 mL to either 1.6 
mL or 1.8 mL as indicated for each experiment). 
Synthesis and chemical characterisation 
Chemical synthesis and characterisation of DFO-ArN3 and DFO-Bn-NCS-onartuzumab were 
performed in accordance with previously reported methods.(1,3) Note, the bioconjugation 
reaction using DFO-Bn-NCS,(4)(5) required pre-purification of the humanized, monovalent 
onartuzumab protein from the formulated solution of MetMAb by standard spin centrifugation 
methods. 
89Zr-radioactive stocks 
A stock solution of [89Zr][Zr(C2O4)4]4- was prepared by adding 89Zr radioactivity from the source 
(222.7 MBq, 140 µL in ~1.0 M aqueous oxalic acid) to an Eppendorf tube. The solution was 
neutralised and made slightly basic by the addition of aliquots of Na2CO3(aq.) (1.0 M stock 
solution, total volume of 180 µL added, final pH ~8.3 – 8.5, final volume ~320 µL, final activity 
= 215.8 MBq). Caution: Acid neutralisation with Na2CO3 releases CO2(g) and care should be 
taken to ensure that no radioactivity escapes the microcentrifuge tube. After CO2 evolution 
ceased, different reactions were performed at the same time using the same stock solutions. 
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Radiochemistry 
Simultaneous photoradiosynthesis of [89Zr]ZrDFO-azepin-onartuzumab 
Simultaneous, one-pot photochemical conjugation and 89Zr-radiolabelling reactions were 
performed in accordance with the following general procedure. A stock solution of DFO-ArN3 
was prepared by dissolving the purified white solid (1, 0.69 mg, 0.978 µmol) in H2O (950 µL) 
and NaOH(aq.) (60 µL of a 0.1 M stock solution). The pH of the DFO-ArN3 solution was 
adjusted to ~8 – 9 by the addition of HCl(aq.) (40 µL of a 0.1 M stock solution) and the final 
concentration of compound 1 was 0.932 mM. Note: DFO-ArN3 (1) is sparingly soluble at high 
pH and starts to precipitate slowly when the pH decreases below ~9. Reactions were performed 
in optically transparent and colourless 2 mL glass vials equipped with small magnetic stirring 
bars.  
Photoradiosynthesis of [89Zr]ZrDFO-azepin-onartuzumab for animal experiments 
To a glass vial containing H2O (30 µL; chelex treated 18.2 MΩ.cm) was added an aliquot of the 
DFO-ArN3 (1) stock solution (40 µL, 37.3 nmol). Then an aliquot of the neutralised stock 
solution of [89Zr][Zr(C2O4)4]4- was added (70 µL, 45.2 MBq). Then an aliquot of the stock 
solution of MetMAb was added (fully formulated, stock concentration = 60 mg/mL, 
MW(onartuzumab) = 99,180 Da, volume added = 10 µL, protein mass = 0.6 mg, protein moles = 
6.05 nmol). The initial chelate-to-mAb ratio was 6.15 to 1. The reaction pH was measured and 
was between 7.9 – 8.3. The total reaction volume was ~150 µL giving a final [mAb] = 40.3 µM, 
and a final [DFO-ArN3] = 248 µM. The reaction was stirred gently at room temperature and 
irradiated directly from the top of the vial for 10 min. Previous experiments using this reaction 
geometry confirmed that this was sufficient to affect ~100% photochemical reaction of the aryl 
azide group on compound 1.(1) After the irradiation, reactions were then quenched by the 
addition of DTPA (10 µL, 50 mM, pH7) and aliquots of the crude reaction mixtures were 
purified by preparative PD-10-SEC (collecting the 0.0 – 1.6 mL high molecular weight fraction 
using sterile PBS as an eluent). Crude and pure mixtures were analysed by using analytical radio-
ITLC, PD-10-SEC and SEC-HPLC. The isolated decay corrected radiochemical yield (RCY) of 
[89Zr]ZrDFO-azepin-onartuzumab was 24.8% (n = 1) and the lower limit of the molar activity of 
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the product (estimated by assuming no protein losses) was ~1.5 MBq/nmol of protein, with an 
activity concentration of 3.87 MBq/mL. The radiochemical purity of the purified samples of 
[89Zr]ZrDFO-azepin-onartuzumab was estimated to be ~90% (measured by SEC-HPLC).  
Preparation of [89Zr]ZrDFO-azepin-onartuzumab doses for injection 
An aliquot of (2.463 MBq) of the purified and formulated sample of [89Zr]ZrDFO-azepin-
onartuzumab was added to a sterile vial and diluted with sterile PBS to a final volume of 1.1 mL. 
Syringes containing an average of 222 ± 15 µL were drawn with the average dose containing 
0.471 ± 0.047 MBq (equivalent to 30.3 ± 0.31 µg of protein, 0.336 ± 0.031 nmol of protein).  
For the competitive inhibition (blocking) experiments, a separate aliquot (2.410 MBq) of 
the purified and formulated sample of [89Zr]ZrDFO-azepin-onartuzumab was added to a sterile 
vial. Then an aliquot of the stock solution of MetMAb (fully formulated; 60 mg/mL, 83 µL, 4.98 
mg of protein) was added and the mixture was diluted with sterile PBS to a final volume of 1.1 
mL. Syringes containing an average of ~208 ± 3 µL were drawn with the average dose 
containing 0.433 ± 0.011 MBq (equivalent to 971 ± 14 µg of protein, 9.79 ± 0.144 nmol of 
protein – a 29-fold increase in the administered protein mass for these blocking doses compared 
to the normal doses). 
Classical radiosynthesis of [89Zr]ZrDFO-Bn-NCS-onartuzumab 
Radiosynthesis of [89Zr]ZrDFO-Bn-NCS-onartuzumab for animal experiments 
Conjugated DFO-Bn-NCS-onartuzumab was prepared as previously reported(3) using the 
standard protocol from Vosjan et al.(4) Radiolabelling with [89Zr][Zr(C2O4)4]4- was 
accomplished by using standard procedures.(6) Briefly, an aliquot of DFO-Bn-NCS-
onartuzumab (65 µL formulated in saline, stock protein concentration = 3.84 mg/mL, pH7, 
protein mass = 0.250 mg, protein moles = 2.52 nmol) was added to an Eppendorf tube containing 
water (107 µL; chelex treated 18.2 MΩ.cm). Then an aliquot of the neutralised stock solution of 
[89Zr][Zr(C2O4)4]4- was added (60 µL, 39.4 MBq,). The reaction pH was measured and was 
between 7.9 – 8.3. The total reaction volume was ~232 µL giving a final [mAb] = 10.9 µM. The 
reaction was incubated at room temperature for ~45 min. and was then quenched by the addition 
of DTPA (10 µL, 50 mM, pH7). Aliquots of the crude reaction mixtures were purified by 
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preparative PD-10-SEC (collecting the 0.0 – 1.6 mL high molecular weight fraction using sterile PBS 
as an eluent). Crude and pure mixtures were analysed by using analytical radio-ITLC, PD-10-SEC and 
SEC-HPLC. The isolated decay corrected radiochemical yield (RCY) of
[89Zr]ZrDFO-azepin-onartuzumab was >97% (n = 1) and the lower limit of the molar activity of the 
product (estimated by assuming no protein losses) was ~14.0 MBq/nmol of protein, with an activity 
concentration of 19.0 MBq/mL. The radiochemical purity of the purified samples of
[89Zr]ZrDFO-azepin-onartuzumab was estimated to be >97% (measured by SEC-HPLC).
Preparation of [89Zr]ZrDFO-Bn-NCS-onartuzumab doses for injection 
An aliquot of (2.463 MBq) of the purified and formulated sample of [89Zr]ZrDFO-Bn-NCS-
onartuzumab was added to a sterile vial and diluted with sterile PBS to a final volume of 1.1 mL. 
Syringes containing an average of 210 ± 2 µL were drawn with the average dose containing 0.571 
± 0.016 MBq (equivalent to 4.04 ± 0.15 µg of protein, 0.041 ± 0.001 nmol of protein).  
Supplemental Figure 2. Radio-iTLC chromatograms recorded during the production of 
[89Zr]ZrDFO-Bn-NCS-onartuzumab and [89Zr]ZrDFO-azepin-onartuzumab for use in animal 
studies. 
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Optimisation of the photoradiosynthesis of [89Zr]ZrDFO-azepin-onartuzumab 
Effect of changing the initial chelate-to-mAb ratio and protein concentration 
Experiments were performed to measure the effect of altering the initial chelate-to-mAb ratio on 
the efficiency of the simultaneous, one-pot photochemical conjugation and 89Zr-radiolabelling of 
onartuzumab (using fully formulated MetMAb). Photoradiosynthesis experiments were set-up in 
an identical fashion to the reaction used to produce the dose for use in animal experiments. 
Unless otherwise stated, all reactions were stirred gently and were performed in triplicate using 
independent replicates. In all cases, the final reaction volume was 160 µL. All reactions were 
irradiated using 365 nm light for 10 min at ambient temperature. The protein concentration of the 
stock solution of formulated MetMAb was 60 mg/mL. The [DFO-ArN3] was 0.932 mM. The 
same neutralised stock solution of [89Zr][Zr(C2O4)4]4- was used throughout and all experiments 
were performed on the same day to limit the effects of changes in molar activity. Full details are 
given in Supplemental Table 1. 
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Supplemental Table 1. Reaction parameters used during the optimisation of the one-pot photoradiosynthesis of [89Zr]ZrDFO-azepin-
onartuzumab starting from formulated MetMAb. 
Parameter Reactions 
A, B and C 
Reactions 
D, E and F 
Reactions 




K and L 
Reactions 
M and N 
Reactions 
O and P 
Reactions 
Q and R 
Vol. MetMAb stock / µL 10 10 10 10 3.2 1 0.32 0.1 
n(mAb) / nmol 6.05 6.05 6.05 6.05 1.91 0.605 0.19 0.06 
Vol. DFO-ArN3 stock / µL 30 15 5 30 30 30 30 30 
n(DFO-ArN3) / nmol 27.95 13.97 4.66 27.95 27.95 27.95 27.95 27.95 
Initial chelate-to-mAb ratio 4.62 2.31 0.77 4.62 14.6 46.2 146.1 461.9 
Radiochemical conversion (RCC) 
/ % measured from SEC-HPLC 
for each replicate 
A = 57.1 
B = 61.9 
C = 51.9 
D = 63.8 
E = 56.0 
F = 58.2 
G = 59.6 
H = 56.1 
I = 59.5 
J = 56.5 K = 23.6 
L = 25.6 
M = 27.5 
N = 18.7 
O = 6.7 
P = 5.6 
Q = 13.7 
R = 8.6 
Average RCC ± one standard 
deviation (s.d.) / %  
56.9 ± 4.1 59.3 ± 3.3 58.4 ± 1.6 56.5 24.6 ± 1.4 23.1 ± 6.2 6.1 ± 0.8 11.1 ± 3.6 
Isolated decay corrected 
radiochemical yield (RCY) / %a 
41.2 ± 10.6 33.7 ± 5.8 34.9 ± 10.4 Not determined Not determined Not determined Not determined Not determined 
Average radiochemical purity 
(RCP) /% of the purified samples 
measured by SEC-HPLC 
91.6 ± 0.6 91.3 ± 1.8 90.7 ± 2.3 Not determined Not determined Not determined Not determined Not determined 
a RCY determined after isolation using preparative PD-10 SEC. b n = 1 replicate. 
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Stability studies 
The stability of [89Zr]ZrDFO-azepin-onartuzumab and [89Zr]ZrDFO-Bn-NCS-onartuzumab with 
respect to change in radiochemical purity due to loss of radioactivity from the protein fraction 
was investigated in vitro by incubation in human serum. Aliquots (80 µL) of the purified and 
formulated radiotracers were added to a solution of human serum (320 µL) giving a total reaction 
volume of 400 µL. Solutions were incubated at 37 oC and samples were withdrawn at various 
time points up to 48 h for analysis by SEC-HPLC measurements. The stability was monitored by 
quantifying the radioactivity associated with intact [89Zr]ZrDFO-azepin-onartuzumab from 
integration of the decay corrected and baseline corrected SEC-HPLC radioactive 
chromatograms.  
Supplemental Figure 3. Radioactive SEC-HPLC chromatograms recorded from samples 
[89Zr]ZrDFO-Bn-NCS-onartuzumab (blue) and [89Zr]ZrDFO-azepin-onartuzumab (green) 
incubated in human serum at 37 oC for up to 48 h.  
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Cell culture 
For cell binding assays, the human gastric cancer cell line MKN-45 (c-MET positive and 
overexpressing, Leibniz Institute DSMZ-German collection of Microorganisms and Cell cultures 
[ACC 409]) was used. Cells were cultured at 37 °C in a humidified 5% CO2 atmosphere. MKN-
45 cells were cultured in RPMI-1640 (without phenol-red). The media was supplemented with 
fetal bovine serum (FBS, 10% (v/v), ThermoFisher Scientific) and penicillin/streptomycin (P/S, 
1% (v/v) of penicillin 10000 U/mL and streptomycin 10 mg/mL). Cells were grown by serial 
passage and were harvested using trypsin-EDTA solution (0.025%). Cells were pelleted (100 g, 
5 min) and resuspended in media before sequential passaging. 
Cell binding assays (immunoreactivity) 
Immunoreactivity was determined using a procedure adapted from Lindmo et al.(7) Briefly, 
MKN-45 cells were harvested and collected by centrifugation (100 g, 5 min). Two concentration 
series of 1:2 dilutions (in triplicate) were prepared in RPMI media. To one series, aliquots of 
purified [89Zr]ZrDFO-azepin-MetMAb (~ 5 ng, ~ 335 Bq, 100 μL PBS) were added, and to the 
other, aliquots of purified [89Zr]ZrDFO-Bn-NCS-MetMAb (~ 5 ng, ~ 3442 Bq, 100 μL PBS) 
were added to each cell concentration. To determine the extent of non-specific binding a fourth 
concentration series of the highest three concentrations was prepared and an ~35,000-fold excess 
of non-functionalised MetMAb (3 μL, 60 mg/mL, 0.18 mg) was added 30 min. before the 
addition of the radiotracer. Three samples of control radiotracers were also prepared to serve as 
standards for total activity added in the vials for each series. Vials were shaken gently at 400 rpm 
at 37 °C in a thermomixer for 4 h to ensure the cells remained in suspension. The cells were then 
pelleted by centrifugation (2000 rpm, 4 °C, 4 min.), the media was removed and the cells were 
washed twice with ice cold PBS with re-pelleting and removal of PBS between each wash. Cell 
associated radioactivity of the washed pellet was measured by using a Hidex gamma counter. 
The immunoreactive fraction was determined as the reciprocal y-intercept from the Lindmo 
transformation.  
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Supplemental Figure 4. Measurement of the immunoreactive fraction of [89Zr]ZrDFO-azepin-
onartuzumab (blue) and [89Zr]ZrDFO-Bn-NCS-onartuzumab (black). (A) Saturation binding 
plot. (B) Lindmo plot.a  
a Data account for differences in radiochemical purity. 
Animals and xenograft models 
All experiments involving mice were conducted in accordance with an animal experimentation 
licence approved by the Zurich Canton Veterinary Office, Switzerland (Jason P. Holland). 
Experimental procedures also complied with guidelines issued in the Guide for the Care and Use 
of Laboratory Animals.(8) Female athymic nude mice (Crl:NU(NCr)-Foxn1nu, 20 – 25 g, 4 – 8 
weeks old) were obtained from Charles River Laboratories Inc. (Freiburg im Breisgau, 
Germany), and were allowed to acclimatise at the University of Zurich Laboratory of Animal 
Science vivarium for at least 1 week prior to implanting tumour cells. Mice were provided with 
food and water ad libitum. Tumours were induced on the right shoulder or flank by sub-
cutaneous (s.c.) injection of approx. 2.5 × 106 cells. The cells were injected in a 200 μL 
suspension of a 1:1 v/v mixture of PBS and reconstituted basement membrane (Corning® 
Matrigel® Basement Membrane Matrix, obtained from VWR International).(9) Tumours 
developed after a period of between 7 – 14 days. Tumour volume (V / mm3) was estimated by 
external Vernier calliper measurements of the longest axis, a / mm, and the axis perpendicular to 
the longest axis, b / mm. The tumours were assumed to be spheroidal and the volume was 
calculated in accordance with Equation S1.  
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(Equation S1) 
Small-animal PET imaging 
All mice injected with cancer cells developed tumours and the average volume of the MKN-45 
tumours was 577 ± 424 mm3 (n = 12 mice; volume range = 135 – 1323 mm3). Mice were 
randomised before the study. The tail of each mouse was warmed gently using a warm water 
bath immediately before administering [89Zr]ZrDFO-azepin-onartuzumab (normal group n = 4 
mice / group, where each dose contained activity = 0.471 ± 0.047 MBq, equivalent to 30.3 ± 0.31 
µg of protein, 0.336 ± 0.031 nmol of protein, in 222 ± 15 µL sterile PBS) via intravenous (i.v.) 
tail-vein injection (t = 0 h). Competitive inhibition studies were also performed to investigate the 
specificity and biological activity of the radiotracer in vivo (blocking group: n = 4 mice / group, 
where each dose contained activity = 0.433 ± 0.011 MBq, equivalent to 971 ± 14 µg of protein, 
9.79 ± 0.144 nmol of protein, in 208 ± 3 µL sterile PBS). For comparison with standard 
conjugation and radiolabelling chemistry, PET imaging was also performed on a group of mice 
administered with [89Zr]ZrDFO-Bn-NCS-onartuzumab (normal group n = 4 mice / group, where 
each dose contained activity 0.571 ± 0.016 MBq, equivalent to 4.04 ± 0.15 µg of protein, 0.041 ± 
0.001 nmol of protein, in 210 ± 2 µL sterile PBS). Full details on radioactive dose preparation 
are given in the Radiochemistry section above.  
PET imaging experiments were conducted on a Genesis G4 PET/X-ray scanner (Sofie 
Biosciences, Culver City, CA).(10) Approximately 5 minutes prior to recording each PET image, 
mice were anesthetised by inhalation of between 2 – 4% isoflurane (AttaneTM, Piramal 
Enterprises Ltd, India, supplied by Provet AG, Lyssach, Switzerland)/oxygen gas mixture and 
placed on the scanner bed in the prone position. PET images were recorded at various time-
points between 0 h and 72 h post-administration of the radiotracer. During image acquisition, the 
respiration rate of the animal was monitored via live video feed and anaesthesia was maintained 
by an experience animal experimenter by controlling the isoflurane dose between 1.5 – 2.0%. 
List-mode data were acquired for 10 min. using a γ-ray energy window of 150–650 keV, and a 
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coincidence timing window of 20 ns. Images were reconstructed by iterative ordered subset 
maximum expectation (OSEM; 60 iterations) protocols. The reported reconstructed spatial 
resolution is 2.4 µL at the centre of the field-of-view (FOV). Image data were normalised to 
correct for non-uniformity of response of the PET, attenuation, random events, dead-time count 
losses, positron branching ratio, and physical decay to the time of injection, but no scatter or 
partial-volume averaging correction was applied. An empirically determined system calibration 
factor (in units of [Bq/voxel]/[MBq/g] or [Bq/cm3]/[MBq/g]) for mice was used to convert voxel 
count rates to activity concentrations. The resulting image data were normalised to the 
administered activity to parameterise images in terms of %ID cm-3 (equivalent to units of %ID/g 
assuming a tissue density of unity). Images were analysed by using VivoQuantTM 3.5 patch 2 
software (InviCRO, Boston, MA). For image quantification and measurements of time-activity 
curves (TACs), 3-dimensional volumes-of-interest (VOIs) were drawn manually to determine the 
maximum and mean accumulation of radioactivity (in units of %ID cm-3 and decay corrected to 
the time of injection) in various tissues. Where appropriate, data were also converted into mean 
standardised uptake values (SUVmean). 
Biodistribution studies 
Biodistribution studies were conducted after the final imaging time point to evaluate the 
radiotracer uptake in tumour-bearing mice. Animals (n = 4 mice / group) were anaesthetised 
individually by isoflurane and euthanised by isoflurane asphyxiation followed by terminal 
exsanguination. Note: one mouse was excluded from the analysis of the data from the normal 
group (vide supra). A total of 15 tissues (including the tumour) were removed, rinsed in water, 
dried in air for approx. 2 min., weighed and counted on a calibrated gamma counter for 
accumulation of activity. The mass of radiotracer formulation injected into each animal was 
measured and used to determine the total number of counts per minute (cpm) injected into each 
mouse by comparison to a standard syringe of known activity and mass. Count data were 
background- and decay-corrected, and the tissue uptake for each sample (determined in units of 
percentage injected dose per gram [%ID g-1]) was calculated by normalisation to the total amount 
of activity injected for each individual animal. For comparison purposes, data are also presented 
in terms of SUV.  
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Effective half-life, t1/2(eff) 
The effective half-lives t1/2(eff) of [89Zr]ZrDFO-azepin-onartuzumab and [89Zr]ZrDFO-Bn-NCS-
onartuzumab were measured in the same athymic nude mice used for small-animal PET imaging 
and end time point biodistribution. Total internal radioactivity was measured as a function of 
time by using a dose calibrator. 
Statistical analysis 
Where appropriate, data were analysed by the unpaired, two-tailed Student’s t-test. Differences 
at the 95% confidence level (P-value <0.05) were considered to be statistically significant. Data 
analysis was performed using Microsoft Excel for MAC (version 16.16.10) and GraphPad Prism 
7 for MAC OS X (version 7.0e). 
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PET imaging results 
Supplemental Figure 5. Temporal PET images recorded in athymic nude mice bearing MKN-
45 tumours on the right flank at time points between 0 h to 72 post-administration of (top) 
[89Zr]ZrDFO-Bn-NCS-onartuzumab, (middle) [89Zr]ZrDFO-azepin-onartuzumab (normal 
group), and (bottom) [89Zr]ZrDFO-azepin-onartuzumab (blocking group). T = tumour, H = heart, 
L = liver, Sp = spleen. Coronal and axial planes are through the tumour centre. 
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Supplemental Figure 6. Maximum intensity projection (MIP) PET images recorded in athymic 
nude mice bearing MKN-45 tumours on the right flank at time points between 0 h to 72 post-
administration of (top) [89Zr]ZrDFO-Bn-NCS-onartuzumab, (middle) [89Zr]ZrDFO-azepin-
onartuzumab (normal group), and (bottom) [89Zr]ZrDFO-azepin-onartuzumab (blocking group). 
T = tumour, H = heart, L = liver, Sp = spleen, B = bladder, K = kidney. 
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Supplemental Figure 7. Time-activity bar chart showing the activity associated with different 
tissues (volumes-of-interest, VOI) versus time (from 0 to 72 h post-administration). Data 
presented are based on quantification of the PET images (in units of %ID cm-1) for [89Zr]ZrDFO-
Bn-NCS-onartuzumab (blue bars), [89Zr]ZrDFO-azepin-onartuzumab (normal group; red-to-
yellow bars), and [89Zr]ZrDFO-azepin-onartuzumab (blocking group; black-to-white bars). 
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Supplemental Figure 8. Plot of the measured activity retained in each mouse versus time.a Data 
were used to estimate the effective and biological half-lives of [89Zr]ZrDFO-Bn-NCS-
onartuzumab and [89Zr]ZrDFO-azepin-onartuzumab. 
a Data account for differences in radiochemical purity. 
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Biodistribution data 
Supplemental Figure 9. Bar chart showing ex vivo biodistribution data (SUV) for the uptake of 
[89Zr]ZrDFO-Bn-NCS-onartuzumab (blue bars), [89Zr]ZrDFO-azepin-onartuzumab (normal 
group, white bars), and [89Zr]ZrDFO-azepin-onartuzumab (blocking group, red bars) in mice 
bearing MKN-45 tumours. Data were recorded after the final imaging time point at 72 h post-
injection. Student’s t-test: (ns) not significant, (*) P-value < 0.05, (**) P-value < 0.01, (***) P-
value < 0.001. 
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Supplemental Figure 10. Bar chart showing tumour-to-tissue contrast ratio calculated from the 
ex vivo biodistribution data (recorded at 72 h post-administration in units of %ID g-1) for the 
uptake of [89Zr]ZrDFO-Bn-NCS-onartuzumab (blue bars), [89Zr]ZrDFO-azepin-onartuzumab 
(normal group, white bars), and [89Zr]ZrDFO-azepin-onartuzumab (blocking group, red bars) in 
mice bearing MKN-45 tumours.  
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Supplemental Table 2. Ex vivo biodistribution data measured at 72 h after i.v. administration of 
89ZrDFO-azepin-onartuzumab (normal and blocking groups) and 89ZrDFO-Bn-NCS-
onartuzumab in female athymic nude mice bearing subcutaneous MKN-45 tumors. [a] Uptake 
data are expressed as the mean %ID g-1 ± one standard deviation (S.D.). [b] Errors for the tumor-
to-tissue ratios are calculated as the standard deviations based on ratios from dependent pairs. 
89ZrDFO-azepin-onartuzumab 
(normal group, n = 4) 
89ZrDFO-azepin-onartuzumab 
(blocking group, n = 4) 
89ZrDFO-Bn-NCS-onartuzumab 
(control group, n = 4) 
Tissue Uptake / %ID g-1 
± S.D.[a] 
Tumor-to-tissue 
contrast ratio ± 
S.D.[b]
Uptake / %ID g-1 
± S.D.[a] 
Tumor-to-tissue 
contrast ratio ± 
S.D.[b]
Uptake / %ID g-1 
± S.D.[a] 
Tumor-to-tissue 
contrast ratio ± 
S.D.[b]
Blood 4.49 ± 1.79 3.53 ± 0.36 4.35 ± 0.27 1.46 ± 0.08 4.50 ± 2.98 5.15 ± 0.99 
Tumor 15.37 ± 5.21 1.00 6.34 ± 0.47 1.00 21.38 ± 11.57 1.00 
Heart 1.98 ± 0.83 8.05 ± 0.97 1.92 ± 0.15 3.30 ± 0.18 2.05 ± 1.20 10.52 ± 0.91 
Lungs 2.88 ± 1.02 5.39 ± 0.54 2.69 ± 0.36 2.38 ± 0.17 3.23 ± 1.72 6.59 ± 0.55 
Liver 6.56 ± 4.03 3.11 ± 1.72 4.12 ± 0.94 1.60 ± 0.36 18.84 ± 6.03 1.38 ± 1.07 
Spleen 3.10 ± 0.50 4.87 ± 1.23 3.49 ± 1.42 2.02 ± 0.66 5.22 ± 1.10 4.34 ± 2.79 
Stomach 0.61 ± 0.23 25.25 ± 3.07 0.48 ± 0.10 13.63 ± 2.45 0.96 ± 0.33 21.22 ± 5.24 
Pancreas 0.76 ± 0.21 19.95 ± 1.93 0.69 ± 0.04 9.13 ± 0.40 0.92 ± 0.25 22.31 ± 7.50 
Kidney 11.28 ± 2.62 1.35 ± 0.36 40.05 ± 3.27 0.16 ± 0.01 7.64 ± 1.80 2.66 ± 0.89 
Sm. Int. 0.82 ± 0.10 18.55 ± 5.40 0.73 ± 0.11 8.82 ± 1.06 1.38 ± 0.46 15.97 ± 7.79 
Large Int. 0.76 ± 0.11 21.15 ± 8.55 0.58 ± 0.12 11.27 ± 1.82 1.79 ± 0.18 12.41 ± 7.50 
Fat 1.21 ± 0.68 14.46 ± 5.71 2.06 ± 1.06 3.55 ± 1.37 2.19 ± 1.19 9.92 ± 4.09 
Muscle 0.58 ± 0.24 28.26 ± 5.49 0.53 ± 0.03 12.00 ± 1.49 0.62 ± 0.26 33.13 ± 5.06 
Bone 2.50 ± 1.08 7.08 ± 3.93 1.75 ± 0.36 3.74 ± 0.81 2.18 ± 1.58 10.88 ± 4.46 
Skin 1.40 ± 0.57 11.49 ± 1.79 1.77 ± 0.57 3.80 ± 0.94 1.52 ± 0.13 13.75 ± 6.88 
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